Publication

Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients

Ochi, T., Vyalova, N. M., Losenkov, I. S., Levchuk, L. A., Osmanova, D. Z., Mikhalitskaya, E. V., Loonen, A. J. M., Bosker, F. J., Simutkin, G. G., Bokhan, N. A., Wilffert, B. & Ivanova, S. A., 1-Dec-2019, In : Journal of Affective Disorders. 259, p. 432-439 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients

    Final publisher's version, 446 KB, PDF document

    Request copy

DOI

  • Taichi Ochi
  • Natalya M. Vyalova
  • Innokentiy S. Losenkov
  • Lyudmila A. Levchuk
  • Diana Z. Osmanova
  • Ekaterina V. Mikhalitskaya
  • Anton J. M. Loonen
  • Fokko J. Bosker
  • German G. Simutkin
  • Nikolay A. Bokhan
  • Bob Wilffert
  • Svetlana A. Ivanova

Background: Brain-derived neurotrophic factor (BDNF) is associated with response to antidepressant drugs in mood and anxiety disorders. Prolactin (PRL) is a pituitary hormone with behavioural effects, acting as a neurotrophic factor within the brain and may be involved in antidepressant response.

Objectives: To investigate the relationship between BDNF and PRL genotypes with antidepressant drug response.

Methods: Prospective inception cohort of 186 Russian treatment-free participants (28 men and 158 women) between 18 and 70 years clinically diagnosed with depressive disorder who initiated antidepressant medication. DNA polymorphisms were genotyped for PRL rs1341239, BDNF rs6265 and rs7124442. Primary outcome was measured by differences in Hamilton Depression Rating Scale (Delta HAM-D) scores between baseline/week two, week two/week four, and baseline/week four. Linear regression and independent t-test determined the significance between polymorphisms and Delta HAM-D.

Results: Comparisons between genotypes did not reveal any significant differences in scores during the first two weeks of treatment. In the latter two weeks, BDNF rs7124442 homozygous C patients responded significantly worse in comparison to homozygous T patients during this period. Further analysis within women and in postmenopausal women found a similar comparison between alleles.

Limitations: Study lasted four weeks, which may be considered short to associate genuine antidepressant effects.

Conclusions: Patients taking tricylic antidepressants were noted to have a significant improvement in Delta HAM-D compared to patients taking SSRIs. Homozygous C BDNF rs712442 patients were found to respond significantly worse in the last two weeks of treatment.

Original languageEnglish
Pages (from-to)432-439
Number of pages8
JournalJournal of Affective Disorders
Volume259
Publication statusPublished - 1-Dec-2019

    Keywords

  • Major depressive disorder, Prolactin, Brain derived neurotrophic factor, rs6265, rs7124442, Antidepressant response, CIRCUITS REGULATING PLEASURE, PSYCHIATRY WFSBP GUIDELINES, TRUE DRUG RESPONSE, PROLACTIN GENE, BIOLOGICAL TREATMENT, NEUROTROPHIC FACTOR, WORLD FEDERATION, ESTROGEN, BRAIN, POLYMORPHISM

View graph of relations

ID: 99951862